Clofibrate


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0003094 Glomerular filtration Increases phenotype PMID:9453308
GO:0004449 Isocitrate dehydrogenase (nad+) activity Increases phenotype PMID:8468521
GO:0004457 Lactate dehydrogenase activity Increases phenotype PMID:26558470
GO:0004784 Superoxide dismutase activity Increases phenotype PMID:31710167
GO:0006094 Gluconeogenesis Increases phenotype PMID:633072
GO:0006099 Tricarboxylic acid cycle Affects phenotype PMID:8468521
GO:0006306 Dna methylation Affects phenotype PMID:33549593
GO:0006309 Apoptotic dna fragmentation Increases phenotype PMID:16465232
GO:0006695 Cholesterol biosynthetic process Decreases phenotype PMID:28495587
GO:0006750 Glutathione biosynthetic process Affects phenotype PMID:31710167
GO:0006915 Apoptotic process Increases phenotype PMID:10951269; PMID:12518023; PMID:16465232; PMID:16465232; PMID:9674879; PMID:16502264; PMID:9674879
GO:0007049 Cell cycle Decreases phenotype PMID:12699904
GO:0008206 Bile acid metabolic process Affects phenotype PMID:28495587
GO:0008217 Regulation of blood pressure Increases phenotype PMID:18596730; PMID:20981147; PMID:9453308
GO:0008283 Cell population proliferation Affects phenotype PMID:10951269; PMID:12699904; PMID:28495587; PMID:31710167
GO:0008610 Lipid biosynthetic process Affects phenotype PMID:27089845; PMID:6162901
GO:0016042 Lipid catabolic process Increases phenotype PMID:1019147; PMID:162783; PMID:31710167
GO:0016615 Malate dehydrogenase activity Increases phenotype PMID:8468521
GO:0018158 Protein oxidation Increases phenotype PMID:31710167
GO:0019852 L-ascorbic acid metabolic process Affects phenotype PMID:31710167
GO:0035640 Exploration behavior Affects phenotype PMID:31710167
GO:0035812 Renal sodium excretion Affects phenotype PMID:9453308
GO:0042178 Xenobiotic catabolic process Increases phenotype PMID:9817083; PMID:9817083; PMID:9929512; PMID:9929512
GO:0042311 Vasodilation Affects phenotype PMID:23422569
GO:0042412 Taurine biosynthetic process Decreases phenotype PMID:28495587
GO:0046209 Nitric oxide metabolic process Affects phenotype PMID:31710167
GO:0046466 Membrane lipid catabolic process Decreases phenotype PMID:17292345
GO:0046620 Regulation of organ growth Increases phenotype PMID:633072
GO:0050665 Hydrogen peroxide biosynthetic process Affects phenotype PMID:31710167
GO:0060612 Adipose tissue development Increases phenotype PMID:9543393
GO:0061518 Microglial cell proliferation Increases phenotype PMID:31710167
GO:1904251 Regulation of bile acid metabolic process Affects phenotype PMID:28973556; PMID:29175453; PMID:29175453
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.